Biomarin Pharmaceutical Inc (BMRN)

Cash ratio

		Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Cash and cash equivalents	US$ in thousands	1,250,110	1,213,820	1,048,800	942,842	675,448	972,150	746,996	755,127	785,414	694,381	580,074	724,531	761,515	619,802	605,440	587,276	617,143	641,533	667,313	649,158
Short-term investments	US$ in thousands	227,731	218,309	223,532	194,864	254,996	252,201	299,584	318,683	340,431	476,577	572,017	567,006	512,253	489,945	450,798	426,599	462,333	481,864	420,178	416,228
Total current liabilities	US$ in thousands	798,438	684,247	628,213	606,988	715,658	1,067,340	1,087,900	1,177,020	1,163,220	597,231	598,231	588,884	521,020	464,727	490,418	539,822	514,898	443,344	430,035	492,548
Cash ratio		1.85	2.09	2.03	1.87	1.30	1.15	0.96	0.91	0.97	1.96	1.93	2.19	2.44	2.39	2.15	1.88	2.10	2.53	2.53	2.16

September 30, 2025 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,250,110K + $227,731K) ÷ $798,438K
= 1.85

Peer comparison

Sep 30, 2025

Company name

Symbol

Cash ratio

Biomarin Pharmaceutical Inc

BMRN

1.85

Arrowhead Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc